Scaling therapeutic discovery for diseases of aging
gordian.png
 
background-03+with+grad.jpg
 
 

We Are pioneering a novel discovery platform to radically improve drug development for complex diseases of aginG.

Read what makes us different.

 
 
 
Daniel Fuentes

Daniel Fuentes

Martin Borch Jensen

Martin Borch Jensen

Francisco LePort

Francisco LePort

Chris Towne

Chris Towne

 
 
Induja Chandrikumar

Induja Chandrikumar

Chris Carrico

Chris Carrico

Ian Driver

Ian Driver

 
 

Join our team!

 
 

AAV development lead

This role combines high-level strategic leadership with ground level experimental work. Your first objective is to set up production of AAV serotypes for Gordian.

Animal specialist

By processing our experimental tissue samples for sequencing, your work will directly determine the quality of data produced by Gordian.

 
 

our advisors and Investors span expertise in aging biology, screening technology, Gene Therapy, and biotech corporate strategy

 
 
 
Tom Rando, Stanford (Advisor, Aging Biology)

Tom Rando, Stanford (Advisor, Aging Biology)

Randy Platt, ETH Zurich (Advisor, Genomics)

Randy Platt, ETH Zurich (Advisor, Genomics)

David Schaffer, UC Berkeley (Advisor, Gene Therapy)

David Schaffer, UC Berkeley (Advisor, Gene Therapy)

Alexander III of Macedon (Advisor, Global Scaling)

Alexander III of Macedon (Advisor, Global Scaling)

 
 
Laura Deming (Investor) Managing Partner, Longevity Fund

Laura Deming (Investor) Managing Partner, Longevity Fund

Edward Lanphier (Investor) Founder and CEO at Sangamo Therapeutics (1995 - 2016)

Edward Lanphier (Investor)
Founder and CEO at Sangamo Therapeutics (1995 - 2016)

Thomas Ebeling (Investor) CEO at Novartis (1998 - 2008), Supervisory Board Member at Bayer

Thomas Ebeling (Investor)
CEO at Novartis (1998 - 2008), Supervisory Board Member at Bayer

 
 
longevity+fund.png
50Y-3_large_transparent.png
gordian.png
NJF_LOGO2_1.png
primemoverslab.png